Paraneoplastic Antibodies EQA
| Accreditation Status: | UKAS Schedule of Accreditation | ||||||||
| Date Scheme started: | 2009 | ||||||||
| Clinical Applicability: | Paraneoplastic autoantibodies are seen with a variety of neurological manifestations and can be associated with an underlying malignancy | ||||||||
| Analytes: |
ANNA-1 (Hu), ANNA-2 (Ri), PCA-1 (Yo), CRMP5 (CV2), Amphiphysin, Ma2 (Ta) and neurological GAD (SER/038) The sample analytes included will depend on their prevalence in the general population, therefore not all analytes may be covered during the year |
||||||||
| Units for Reporting: |
Paraneoplastic Antibodies – present or absent Antibody identification – Analytes from list, ANNA-1 etc |
||||||||
| Samples Distributed: | Liquid format. Normal and pathological human serum | ||||||||
| Number of Distributions per year: | 6 | ||||||||
| Number of Samples per Distribution: | 2 | ||||||||
| Frequency of Distributions: | Every two months as outlined in the Distribution Schedule | ||||||||
| Schedule of Analysis: | Data entry is via the web for the submission of results. Data analysis commences 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics. | ||||||||
| Data Analysis: | Qualitative responses are assessed in relation to the designated response | ||||||||
| Performance Scoring: | MI Scoring | ||||||||
| Criteria of Performance: |
Laboratory performance is classified in terms of OMIS derived from the qualitative responses for all analytes for which the laboratory is registered over a running analytical window of 6 Distributions (12 months) The categories of performance are:
|
||||||||
| Persistent Poor Performance: |
Defined as being in the Poor Performance category for two or more successive Distributions |